Wow_老虎社区_美港股上老虎

4XKEYQ
2021-12-20

Wow

Summit Therapeutics Shares Fall nearly 30% After Failing to Meet Endpoint in Phase 3 Ri-CoDIFy Study

Summit Therapeutics Inc. shares fell nearly 30% to $3.5 after the company said its Phase 3 Ri-CoDIFy

Summit Therapeutics Shares Fall nearly 30% After Failing to Meet Endpoint in Phase 3 Ri-CoDIFy Study

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":693872600,"tweetId":"693872600","gmtCreate":1640008953376,"gmtModify":1640008953757,"author":{"id":3575807346407979,"idStr":"3575807346407979","authorId":3575807346407979,"authorIdStr":"3575807346407979","name":"4XKEYQ","avatar":"https://static.tigerbbs.com/de3f10a9c3304a65bad52cfc9b4792f0","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":38,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wow</p></body></html>","htmlText":"<html><head></head><body><p>Wow</p></body></html>","text":"Wow","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693872600","repostId":1138448212,"repostType":4,"repost":{"id":"1138448212","kind":"news","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1640008237,"share":"https://www.laohu8.com/m/news/1138448212?lang=&edition=full","pubTime":"2021-12-20 21:50","market":"us","language":"en","title":"Summit Therapeutics Shares Fall nearly 30% After Failing to Meet Endpoint in Phase 3 Ri-CoDIFy Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1138448212","media":"Dow Jones","summary":"Summit Therapeutics Inc. shares fell nearly 30% to $3.5 after the company said its Phase 3 Ri-CoDIFy","content":"<p>Summit Therapeutics Inc. shares fell&nbsp;nearly 30% to $3.5 after the company said its Phase 3 Ri-CoDIFy study didn't meet its primary endpoint for superiority for the treatment of C. difficle infection.</p>\n<p><img src=\"https://static.tigerbbs.com/5780de0c9ef3f0248ec3fa67eaa2037e\" tg-width=\"703\" tg-height=\"593\" referrerpolicy=\"no-referrer\"></p>\n<p>The investigational drug, ridinilazole, resulted in a higher observed sustained clinicial response than the antibiotic vancomycin but not superiority, Summit said. Sustained clinical response is defined as clinical response of the treated episode of CDI and no recurrence of the infection through 30 days after the end of treatment, the company said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Summit Therapeutics Shares Fall nearly 30% After Failing to Meet Endpoint in Phase 3 Ri-CoDIFy Study </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSummit Therapeutics Shares Fall nearly 30% After Failing to Meet Endpoint in Phase 3 Ri-CoDIFy Study \n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-20 21:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Summit Therapeutics Inc. shares fell&nbsp;nearly 30% to $3.5 after the company said its Phase 3 Ri-CoDIFy study didn't meet its primary endpoint for superiority for the treatment of C. difficle infection.</p>\n<p><img src=\"https://static.tigerbbs.com/5780de0c9ef3f0248ec3fa67eaa2037e\" tg-width=\"703\" tg-height=\"593\" referrerpolicy=\"no-referrer\"></p>\n<p>The investigational drug, ridinilazole, resulted in a higher observed sustained clinicial response than the antibiotic vancomycin but not superiority, Summit said. Sustained clinical response is defined as clinical response of the treated episode of CDI and no recurrence of the infection through 30 days after the end of treatment, the company said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138448212","content_text":"Summit Therapeutics Inc. shares fell nearly 30% to $3.5 after the company said its Phase 3 Ri-CoDIFy study didn't meet its primary endpoint for superiority for the treatment of C. difficle infection.\n\nThe investigational drug, ridinilazole, resulted in a higher observed sustained clinicial response than the antibiotic vancomycin but not superiority, Summit said. Sustained clinical response is defined as clinical response of the treated episode of CDI and no recurrence of the infection through 30 days after the end of treatment, the company said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":609,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Summit Therapeutics Shares Fall nearly 30% After Failing to Meet Endpoint in Phase 3 Ri-CoDIFy Study

评论（1）

热议股票